A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Accent Therapeutics
A2 Biotherapeutics Inc.
Arvinas Inc.
GlaxoSmithKline
Pheon Therapeutics
EXoPERT
Orano Med LLC
Novartis
Tempus AI
Travera Inc
Elicio Therapeutics
Palleon Pharmaceuticals, Inc.
Alaunos Therapeutics
Novita Pharmaceuticals, Inc.
ModeX Therapeutics, An OPKO Health Company
Compugen Ltd
Tempus AI
Compugen Ltd
NextCure, Inc.
Revolution Medicines, Inc.
VitaMed Research LLC
DxTerity Diagnostics
NantCell, Inc.
NextCure, Inc.
ADC Therapeutics S.A.
pharmaand GmbH
Klus Pharma Inc.
Kineta Inc.
Blue Note Therapeutics
Health Clinics Limited
MacroGenics
TScan Therapeutics, Inc.
MacroGenics
Novartis
SpeciCare
Petra Pharma
AbbVie
SPGO Research Mannheim GmbH
AbbVie
Altor BioScience
Novartis
INSYS Therapeutics Inc
CritiTech, Inc.
Calando Pharmaceuticals
Altor BioScience
Eisai Inc.
AstraZeneca
Pharmacyclics LLC.